TP53 and neoplasm: Overall, our findings reveal that anticancer treatments enhance CK2-mediated HMGA1 secretion in TP53-mutant PDAC cells, which, through autocrine signaling, drives NPM1 hyperphosphorylation and fuels tumor cell proliferation.